Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
" c/ g4 \3 K* t
: _- \$ o7 C* X2 K v' l4 |/ H$ L! A: V; C; g
Sub-category:
/ V8 u$ t3 }+ P. Y MMolecular Targets 4 P H) d' \( v! E Y
' {& W. q0 ~) ^: q+ }% l1 A
! h6 h+ {. Z f0 g- G) C# uCategory:0 y/ d O: K8 s0 _" o
Tumor Biology
6 @. M# `/ g2 ^$ n/ ]6 z
; l+ O2 V% Q- }5 t7 Y1 K$ x! O. s! v. _; d
Meeting:0 c% }7 `8 ?# `9 u* z9 ^, I3 c
2011 ASCO Annual Meeting & ~/ H) E. a8 U |: L
& K5 }( V) B. X8 [5 O' V% V
: [- L7 B# O. s# MSession Type and Session Title:
6 W y; P- D+ j5 `Poster Discussion Session, Tumor Biology
- e- g r- H; ~! K5 ]% j6 n- O/ L9 q! V* Q& @: p7 Z( s2 z
9 t& t; j. z' A) A0 Y/ i) aAbstract No:- A% R; |8 u3 Y$ c& a
10517 . A) I( w4 o' o8 W9 ?/ x7 D
& P" d+ N. Z" m$ B% U8 e
- C6 \! ~& Y- K4 ?5 [Citation:
' }# r! c, o8 n/ KJ Clin Oncol 29: 2011 (suppl; abstr 10517)
4 F* O/ H' J+ r6 ?+ k7 m0 r6 U# e
/ X' Q2 Y [( B$ @1 ?
1 c, a6 C n( CAuthor(s):
/ O' k: ` X/ aJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
2 D1 [, L n' @3 `# ]" n1 N9 U& M
: b o1 g0 D1 E% G4 |' G8 h U. Q3 p6 ^) b2 f- j+ ?8 f+ Z
- @5 O1 l& o2 X6 g8 P. u, \$ N N0 ]
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
; E2 x3 [3 @2 B* ?4 ]& X/ h- D* U- `4 ~" e2 ]
Abstract Disclosures
$ z, u! k1 {+ W( z6 z: B8 Q4 D
7 C# }4 h$ W4 P! l9 g: y5 V( pAbstract:
4 M; o4 C4 q. x. J) G! u& [. [' d6 n! O+ f- z7 X3 z
% K/ e1 E0 _ F& g) `1 ?0 i# I/ l
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.6 d8 o i Z2 H$ q# {2 `9 k d
! E% I2 }8 H( T/ F1 W
9 K$ N5 O2 b! S. H: H |
8 v! {. t0 {& Z
显身卡
